RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Blood

Volumn 119, Issue 22, 2012, Pages 5229-5238

  Aimiuwu, Josephine ^a   Wang, Hongyan ^a,b   Chen, Ping ^a   Xie, Zhiliang ^a   Wang, Jiang ^a   Liu, Shujun ^b   Klisovic, Rebecca ^b   Mims, Alice ^b   Blum, William ^b   Marcucci, Guido ^a,b   Chan, Kenneth K ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DNA SYNTHESIS; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84861892178     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-382226     Document Type: Article

References (47)

1. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia. 1964;20(4):202-203.
2. Bergy ME, Herr RR. Microbiological production of 5-azacytidine. II. Isolation and chemical structure. Antimicrob Agents Chemother (Bethesda). 1966;6:625-630.
3. Hanka LJ, Evans JS, Mason DJ, Dietz A. Microbiological production of 5-azacytidine. I. Production and biological activity. Antimicrob Agents Chemother (Bethesda). 1966;6:619-624.
4. Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother. 2005;39(10):1700-1709.
5. Murakami T, Li X, Gong J, Bhatia U, Traganos F, Darzynkiewicz Z. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. 1995;55(14):3093-3098.
6. Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacytidine, a DNAmethyltransferase inhibitor, induces ATR-mediated DNAdouble-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718-1727.
7. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30(11):2760-2769.
8. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15(12):3938-3946.
9. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res. 1981;5(6):453-462.
10. Momparler RL. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther. 1985;30(3):287-299.
11. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483-5495.
12. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12(19):5777-5785.
13. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891.
14. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-6418.
15. Chen P, Liu Z, Liu S, et al. A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels. Pharm Res. 2009;26(6):1504-1515.
16. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom. 2006;20(7):1117-1126.
17. Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77(2):504-510.
18. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005;23(17):3906-3911.
19. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003;27(12):1077-1083.
20. Lee Y, Vassilakos A, Feng N, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res. 2003;63(11):2802-2811.
21. Tobler AR, Short S, Andersen MR, et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech. 2005;16(4):398-406.
22. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-1095.
23. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets. 2006;6(5):409-431.
24. Lee T, Karon M, Momparler RL. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res. 1974;34(10):2482-2488.
25. Liacouras AS, Anderson EP. Uridine-cytidine kinase. IV. Kinetics of the competition between 5-azacytidine and the two natural substrates. Mol Pharmacol. 1979;15(2):331-340.
26. Kelecsényi Z, Spencer DL, Caspary WJ. Molecular analysis of 5-azacytidine-induced variants in mammalian cells. Mutagenesis. 2000;15(1):25-31.
27. Amara FM, Chen FY, Wright JA. A novel transforming growth factor-beta 1 responsive cytoplasmic trans-acting factor binds selectively to the 3′-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability. Nucleic Acids Res. 1993;21(20):4803-4809.
28. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005;19(5):631-642.
29. Lin HL, Glazer RI. The comparative effects of 5-azacytidine and dihydro-5-azacytidine on polysomal RNA in Ehrlich ascites cells in vitro. Mol Pharmacol. 1981;20(3):644-648.
30. Cihák A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974;30(5):405-422.
31. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5(2):e9001.
32. Chan KK, Giannini DD, Staroscik JA, Sadee W. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. J Pharm Sci. 1979;68(7):807-812.
33. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8-13.
34. Zielinski WS, Sprinzl M. Chemical synthesis of 5-azacytidine nucleotides and preparation of tRNAs containing 5-azacytidine in its 3′-terminus. Nucleic Acids Res. 1984;12(12):5025-5036.
35. Avramis VI, Biener R, Krailo M, et al. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res. 1987;47(24 Pt 1):6786-6792.
36. Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998;16(1):43-49.
37. Huang A, Fan H, Taylor WR, Wright JA. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res. 1997;57(21):4876-4881.
38. Madlener S, Illmer C, Horvath Z, et al. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett. 2007;245(1-2):156-162.
39. Klisovic RB, Blum W, Wei X, et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res. 2008;14(12):3889-3895.
40. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther. 2002;2(4):437-448.
41. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res. 1983;43(8):3466- 3492.
42. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407.
43. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem. 1988;57:349-374.
44. Koc A, Mathews CK, Wheeler LJ, Gross MK, Merrill GF. Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J Biol Chem. 2006;281(22):15058-15063.
45. Mao SS, Yu GX, Chalfoun D, Stubbe J. Characterization of C439SR1, a mutant of Escherichia coli ribonucleotide diphosphate reductase: evidence that C439 is a residue essential for nucleotide reduction and C439SR1 is a protein possessing novel thioredoxin-like activity. Biochemistry. 1992;31(40):9752-9759.
46. Mao SS, Holler TP, Bollinger JM, Jr., Yu GX, Johnston MI, Stubbe J. Interaction of C225SR1 mutant subunit of ribonucleotide reductase with R2 and nucleoside diphosphates: tales of a suicidal enzyme. Biochemistry. 1992;31(40):9744-9751.
47. Persson AL, Eriksson M, Katterle B, Potsch S, Sahlin M, Sjoberg BM. A new mechanism-based radical intermediate in a mutant R1 protein affecting the catalytically essential Glu441 in Escherichia coli ribonucleotide reductase. J Biol Chem. 1997;272(50):31533-31541.